1 · The patent estate

We filed a priority patent application at the European Patent Office in May 2025, covering the bioactive compositions, their health uses (across gut, neurological, and metabolic indications), and the manufacturing approach. The international (PCT) application was filed on 14 May 2026, claiming that priority, with national-phase entries to follow.

Two follow-on applications are in preparation:

  • A broad combinations application — pairing our actives with commercially available fibers, phenolics, vitamins, live strains, and other adjuncts. This is the combinatorial space our platform is built to explore.
  • A novel-chemical-matter application on new functional matter identified through the discovery engine.

2 · A favorable patent-office opinion

In its Search Opinion on our priority application, the EPO examiner addressed the cognitive rationale behind our lead mechanism directly. In the examiner's words, it is:

"…plausible that a composition able to promote the abundance of A. butyriciproducens may be effective for treating cognitive impairment due to aging and Alzheimer's disease."

An independent patent examiner, on the cognitive rationale behind our lead mechanism.

3 · Trade-secret process

Alongside the patents, the know-how that makes our actives reproducible and cost-efficient — the extraction process and its parameters — is held as a trade secret. Patents disclose; trade secrets don't. Together they create overlapping protection: composition and use under the patent estate, and process under trade secret.

4 · A compounding data moat

The hardest layer to copy is the one that grows. Teroka — our closed wetlab-and-computational loop — generates a proprietary dataset on how the gut ecosystem responds to bioactives and their combinations. It isn't for sale, and it compounds with every cycle of the engine. How the platform works →

Why it adds up

Capital efficiency follows from this. We put money into IP, evidence, and the engine — durable assets that compound in value over time — rather than into D2C marketing.

What does Trilliome's patent cover?
Composition of the bioactives, their health uses, and manufacturing — filed as a priority application at the EPO in May 2025, with the international (PCT) application filed 14 May 2026 and national phases to follow.
What did the EPO Search Opinion say?
That it is "plausible that a composition able to promote the abundance of A. butyriciproducens may be effective for treating cognitive impairment due to aging and Alzheimer's disease."
Is anything protected as a trade secret?
Yes — the extraction process and its parameters.
What stops a competitor from copying the platform?
Layered protection: patents, trade-secret process, and a proprietary dataset that compounds as the engine runs.